Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • plexiform neurofibroma
Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial
Posted inClinical Updates Wellness & Lifestyle

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

Posted by By MedXY 08/03/2025
The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.
Read More
  • Elevated D-Dimer Levels: Beyond Pulmonary Embolism—Uncommon Conditions Many Doctors Overlook
  • Understanding and Managing Alzheimer’s Disease: A Comprehensive Guide
  • Understanding and Managing Seasonal Allergies: A Comprehensive Guide
  • Understanding and Managing Hypertension: A Comprehensive Guide
  • Understanding and Managing Chronic Fatigue Syndrome
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials Dementia diabetes diet epidemiology exercise FDA FDA approval GLP-1 health healthcare HIV Hypertension immunotherapy lifestyle lifestyle intervention longevity MASLD maternal health men's health mental health multiple myeloma nutrition obesity older adults Pediatrics Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes Vaccine walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top